An interventional study of Valacyclovir hydrochloride in Herpes Simplex and HIV Infections, sponsored by Glaxo Wellcome. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-29.
Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.
Among the 14 studies testing valacyclovir in Herpes Genitalis, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 5 with no phase, and was the 1st registered.
70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.
Browse Herpes Genitalis studies →None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →
Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →
Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked.
This study's enrollment of 30 is below the median of 103 across 51 interventional studies indexed under Herpes Genitalis.
Median enrollment 50 across the 11 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Glaxo Wellcome, one of the names counted as GlaxoSmithKline. Under that name alone:
Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
11 studies in Herpes Genitalis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 11 studies in Herpes Genitalis by GlaxoSmithKline, this one is one of 3 with no phase, and was the 1st registered.
GlaxoSmithKline’s Herpes Genitalis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valacyclovir in Herpes Genitalis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Herpes Genitalis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if valacyclovir affects the detection of HIV in genital herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital herpes.
Following evaluation for 2 consecutive episodes of genital herpes in this double-blind, crossover study, 30 HIV-1 positive patients are randomized to receive either valacyclovir or placebo.
All patients are treated for 10 days.
70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.
This study's enrollment of 30 is below the median of 103 across 51 interventional studies indexed under Herpes Genitalis.
Browse Herpes Genitalis studies →Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
First submitted before Glaxo Wellcome became part of GlaxoSmithKline.
Compared within Herpes Genitalis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Herpes Simplex. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
History of to acyclovir or valacyclovir.
Prior Medication:
Excluded:
Systemic anti-HSV therapy within 7 days prior to start of study drug.
Required:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No study locations are listed for this record.
This study is completed, as verified in Jun 1999. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valacyclovir